GH Research PLC (NASDAQ: GHRS) Targets Mental Health Disorders with Innovative Treatments

Company Overview - GH Research PLC (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, specifically advancing GH001, an inhalable bufotenin product candidate for treatment-resistant depression (TRD) [1][6] - Competitors include other biopharmaceutical companies such as Compass Pathways and MindMed [1] Recent Developments - On January 5, 2026, Eddie Hickman from Guggenheim set a price target of $29 for GHRS, indicating a potential upside of approximately 83.5% from the current stock price of $15.80, with a Buy rating reiterated following a management call [2] - The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on GH Research's Investigational New Drug Application (IND) for GH001, allowing the company to advance its global pivotal program in 2026 [3] - In February 2025, GH Research announced that its Phase 2b trial for GH001 successfully met its primary endpoint, showing a significant reduction of 15.2 points in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline on Day 8, compared to an increase of 0.3 points in the placebo group [4] Stock Performance - The stock for GHRS is currently priced at $15.78, reflecting a significant increase of 19.18% with a change of $2.54, and has fluctuated between a low of $15.59 and a high of $19 today [5] - Over the past year, GHRS has reached a high of $20.50 and a low of $7.98, with a market capitalization of approximately $978.8 million and a trading volume of 4,619,702 shares [5]